Zelton Sharp, Ph.D.
Professor, Molecular Medicine
Dr. Z. Dave Sharp's lab explores novel strategies to prevent diseases while mitigating morbidities associated with aging, thereby reducing suffering and looming economic burden.
They study how chronic mTOR inhibition prevents, delays, and/or reduces the severity of cancer while mitigating other negative effects of aging.
Their experiments show this is possible with a novel enteric formulation of rapamycin, eRapa. Their current research goals aim to understand the mechanism of action of eRapa in the prevention of colon cancer using mouse models combined with genetic, epigenetic and protein synthesis profiling technologies.
Publications
Book Chapter |
| Sharp ZD. mTOR, Aging and Cancer: Prospects for Pharmacological Interventions. In: Sharp ZD. Anti-aging drugs: from basic research to clinical practice. England: Royal Society of Chemistry; 2017. |
| Sharp ZD Hasty, P. mTOR, Aging and Cancer: A dangerous link. In: Editors: Monica Mita, Alain Mita, and Eric K. Rowinsky. mTOR Inhibition for Cancer Therapy. Verlag, France: Springer; 2016. p. 277-292. |
Journal Article |
| Dodds SG, Livi CB, Parihar M, Hsu HK, Benavides AD, Morris J, Javors M, Strong R, Christy B, Hasty P, Sharp ZD. Adaptations to chronic rapamycin in mice Pathobiol Aging Age Relat Dis 2016 Jan;6:31688-31688. |
| Christy B, Demaria M, Campisi J, Huang J, Jones D, Dodds SG, Williams C, Hubbard G, Livi CB, Gao X, Weintraub S, Curiel T, Sharp ZD, Hasty P. p53 and rapamycin are additive Oncotarget 2015 Jun;6(18):15802-15813. |
| Calhoun, C, Shivshankar, P, Saker, M, Sloane, LB, Livi, CB, Sharp ZD, Orihuela CJ, Adnot, S, White, E, Richardson AG, Le Saux CJ. Senescent cells contribute to the physiological remodeling of aged lungs Journal of Gerontology- Series A: Biological Sciences and Medical Sciences 2015 Jan;70(1):1-9. |
| Rodriguez KA, Dodds SG, Strong R, Galvan V, Sharp ZD, Buffenstein R. Divergent tissue and sex effects of rapamycin on the proteasome-chaperone network of old mice Front Mol Neurosci 2014 Nov;7:83-83. |
| Hasty P, Livi C, Dodds S, Jones D, Strong R, Javors M, Fischer KE, Sloane L, Murthy K, Hubbard G, Sun L, Hurez V, Curiel TJ, Sharp ZD, and Fischer K. eRapa Restores A Normal Life Span in a FAP Mouse Model Cancer Prev Res (Phila) 2014 Jan;7(1):169-178. |
| Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, Javors MA, Li X, Nadon NL, Nelson JF, Pletcher S, Salmon AB, Z. Dave Sharp, Van Roekel S, Winkleman L, Strong R. Rapamycin-mediated lifespan increase in mice is dose and sex-dependent and metabolically distinct from dietary restriction Aging Cell 2014 Jan;13(3):468-477. |
| Livi CB, Hardman RL, Christy BA, Dodds SG, Jones D, Williams C, Strong R, Bokov A, Javors MA, Ikeno Y, Hubbard G, Hasty P, Sharp ZD. Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors Aging (Albany NY) 2013 Feb;5(2):100-110. |
| Zelton Dave Sharp, Tyler Curiel and Carolina Livi. Chronic mTOR inhibition: preventing cancer to delay aging, or vice versa? Interdisciplinary Topics in Gerontology 2013 Jan;38:1-16. |
| Sharp ZD, Nelson, JF, Strong, R. mTOR, aging and the potential for intervention Experimental Medicine 2013 Jan;. |
| Hsu PY, Hsu HK, Lan X, Juan L, Yan PS, Labanowska J, Heerema N, Hsiao TH, Chiu YC, Chen Y, Liu Y, Li L, Li R, Thompson IM, Nephew KP, Sharp ZD, Kirma NB, Jin VX, Huang TH. Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer Cancer Cell 2013 Jan;24:197-212. |
Not Specified |
| Liss, MA Rickborn, L DiGiovanni, J Bacicha, D DeGraffenried, LA Parihar, M Thompson, IM Sharp ZD. mTOR inhibitors for treatment of low-risk prostate cancer Medical Hypotheses 2018 Feb;117:63-68. |
| Aashish Kabra Essel Marie de Leon Carolina Livi Martin Javors Marlo Nicolas David Henkes Z.Dave Sharp Tyler Curiel Robert Svatek. A PHARMACODYNAMIC PHASE 0/I STUDY OF ORAL RAPAMYCIN IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER THE JOURNAL OF UROLOGY 2015 May;193(4s):e810-e810. |
Grants
Scroll table right to view more
Federal |
|
| Funding Agency | NCI |
| Title | Delaying Intestinal Cancer |
| Status | Active |
| Period | 12/2015 - 11/2020 |
| Role | Principal Investigator |
| Grant Detail | |
Private |
|
| Funding Agency | Glenn Foundation |
| Title | Glenn Foundation for Medical Research |
| Status | Complete |
| Period | 9/2010 - Present |
| Role | Principal Investigator |
| Grant Detail | |
|
|
|
| Funding Agency | Barshop Institute for Longevity and Aging Studies |
| Title | Role of SLC38a1 neutral amino acid transporter in mTOR regulation |
| Status | Active |
| Period | - Present |
| Role | Principal Investigator |
| Grant Detail | |
Education
Scroll table right to view more
| Year | Degree | Discipline | Institution |
| 1981 | PhD | Cell Biology and Human Anatomy | University of Arkansas for Medical Sciences AR |
| 1975 | BS | Biology | University of Arkansas Little Rock , AR |
| 1968 | BA | BBA in Accounting | University of Arkansas Monticello , AR |
| Postdoctoral Fellowship | Depts. of Biology and Biochemistry | Rice University Houston , TX |